Literature DB >> 10078552

Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats.

T M Mason1, T Goh, V Tchipashvili, H Sandhu, N Gupta, G F Lewis, A Giacca.   

Abstract

Prolonged exposure of pancreatic islets to free fatty acids (FFAs) inhibits glucose-stimulated insulin secretion (GSIS) in vitro. However, FFA inhibition of GSIS has not been clearly demonstrated in vivo. We examined the in vivo effect of prolonged elevation of plasma FFAs on GSIS using a two-step hyperglycemic clamp in rats treated with a 48-h intravenous infusion of either 20% Intralipid plus heparin (INT) (5 microl/min plus heparin, 0.1 U/min; n = 8), oleate (OLE) (1.3 microEq/min; n = 6), saline (SAL) (n = 6), or bovine serum albumin (BSA) (vehicle for OLE; n = 5). Because there was no difference in any of the parameters between BSA and SAL rats, these groups were combined as control rats (CONT) (n = 11). At the end of the 48-h OLE/INT/CONT infusions, after an overnight fast, plasma glucose was clamped for 2 h at 13 mmol/l and for another 2 h at 22 mmol/l. Preclamp plasma FFAs were elevated twofold (P < 0.01) versus CONT with both INT and OLE (NS, INT vs. OLE). Preclamp glucose, insulin, and C-peptide levels were higher in INT than in CONT rats (P < 0.05), suggesting insulin resistance, but they were not different in OLE and CONT rats. The insulin and C-peptide responses to the rise in plasma glucose from basal to 13 mmol/l were lower in OLE (336 +/- 72 pmol/l and 1.2 +/- 0.1 nmol/l, P < 0.01 and P < 0.05, respectively) than in CONT (552 +/- 54 and 1.9 +/- 0.1) rats, but they were not different between CONT and INT rats (648 +/- 150 and 2.0 +/- 0.4). The insulin and C-peptide responses to the rise in plasma glucose from 13 to 22 mmol/l were lower in both INT (1,188 +/- 204 pmol/l and 3.0 +/- 0.3 nmol/l, P < 0.01 and P < 0.001) and OLE (432 +/- 60 and 1.7 +/- 0.2, P < 0.001 vs. CONT or INT) rats than in CONT rats (1,662 +/- 174 and 5.0 +/- 0.6). In summary, 1) both INT and OLE decreased GSIS in vivo in rats, and 2) the impairing effect of INT on GSIS was less than that of OLE, which might be due to the different type of fatty acid (mostly polyunsaturated in INT versus monounsaturated as OLE) and/or to differential effects of INT and OLE on insulin sensitivity. In conclusion, prolonged elevation of plasma FFAs can desensitize the insulin secretory response to glucose in vivo, thus inducing a beta-cell defect that is similar to that found in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10078552     DOI: 10.2337/diabetes.48.3.524

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  40 in total

1.  Differential vasomotor effects of insulin on gastrocnemius and soleus feed arteries in the OLETF rat model: role of endothelin-1.

Authors:  Nathan T Jenkins; Jaume Padilla; Jeffrey S Martin; Jacqueline M Crissey; John P Thyfault; R Scott Rector; M Harold Laughlin
Journal:  Exp Physiol       Date:  2013-08-30       Impact factor: 2.969

2.  Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation.

Authors:  R L Hull; K Kodama; K M Utzschneider; D B Carr; R L Prigeon; S E Kahn
Journal:  Diabetologia       Date:  2005-06-04       Impact factor: 10.122

3.  Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans.

Authors:  C Xiao; A Giacca; A Carpentier; G F Lewis
Journal:  Diabetologia       Date:  2006-04-05       Impact factor: 10.122

4.  Chronic effects of different non-esterified fatty acids on pancreatic islets of rats.

Authors:  Yuan Wang; Pei-Yu Wang; Kaneko Takashi
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

5.  The effect of insulin on the intracellular distribution of 14(R,S)-[18F]Fluoro-6-thia-heptadecanoic acid in rats.

Authors:  Xiuli Ci; Frédérique Frisch; François Lavoie; Pascale Germain; Roger Lecomte; Johan E van Lier; François Bénard; André C Carpentier
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

6.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance.

Authors:  Yasuo Terauchi; Iseki Takamoto; Naoto Kubota; Junji Matsui; Ryo Suzuki; Kajuro Komeda; Akemi Hara; Yukiyasu Toyoda; Ichitomo Miwa; Shinichi Aizawa; Shuichi Tsutsumi; Yoshiharu Tsubamoto; Shinji Hashimoto; Kazuhiro Eto; Akinobu Nakamura; Mitsuhiko Noda; Kazuyuki Tobe; Hiroyuki Aburatani; Ryozo Nagai; Takashi Kadowaki
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 7.  Glucolipotoxicity: fuel excess and beta-cell dysfunction.

Authors:  Vincent Poitout; R Paul Robertson
Journal:  Endocr Rev       Date:  2007-11-29       Impact factor: 19.871

8.  Adipose Tissue: A Metabolic Regulator. Potential Implications for the Metabolic Outcome of Subjects Born Small for Gestational Age (SGA).

Authors:  Arianna Maiorana; Chiara Del Bianco; Stefano Cianfarani
Journal:  Rev Diabet Stud       Date:  2007-11-10

9.  IKKβ inhibition prevents fat-induced beta cell dysfunction in vitro and in vivo in rodents.

Authors:  Aleksandar Ivovic; Andrei I Oprescu; Khajag Koulajian; Yusaku Mori; Judith A Eversley; Liling Zhang; Rodolfo Nino-Fong; Gary F Lewis; Marc Y Donath; Michael Karin; Michael B Wheeler; Jan Ehses; Allen Volchuk; Catherine B Chan; Adria Giacca
Journal:  Diabetologia       Date:  2017-07-20       Impact factor: 10.122

10.  Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets.

Authors:  Derek K Hagman; Martin G Latour; Swarup K Chakrabarti; Ghislaine Fontes; Julie Amyot; Caroline Tremblay; Meriem Semache; James A Lausier; Violet Roskens; Raghavendra G Mirmira; Thomas L Jetton; Vincent Poitout
Journal:  Diabetes       Date:  2007-11-08       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.